Department of Neurology, Odense University Hospital, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Br J Cancer. 2013 Feb 19;108(3):715-20. doi: 10.1038/bjc.2012.536. Epub 2013 Jan 15.
Laboratory studies and a single case-control study have suggested a protective effect of statins on the risk of glioma. We wished to investigate the influence of statin use on the risk of glioma in a population-based setting.
We conducted a nationwide case-control study in Denmark based on population-based medical registries. We identified all patients aged 20 to 85 years with a first diagnosis of histologically verified glioma during 2000-2009. These cases were matched on birth year and sex with population controls. Prior use of statins since 1995 was classified into short-term use (<5 years) and long-term use (5+ years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for glioma associated with statin use, adjusted for potential confounders.
A total of 2656 cases and 18,480 controls were included in the study. The risk of glioma was reduced among long-term statin users (OR=0.76; 95% CI: 0.59-0.98) compared with never users of statins, and was inversely related to the intensity of statin treatment among users (OR=0.71; 95% CI: 0.44-1.15 for highest intensity). The inverse association between long-term statin treatment and glioma risk was more pronounced among men aged ≤ 60 years (OR=0.40; 95% CI: 0.17-0.91) compared with men aged 60+ years (OR=0.71; 95% CI: 0.49-1.03). An inverse association was also observed among women aged ≤ 60 years (OR=0.28; 95% CI: 0.06-1.25), but not among women over age 60 years (OR=1.23; 95% CI: 0.82-1.85).
Long-term statin use may reduce the risk of glioma.
实验室研究和一项病例对照研究表明，他汀类药物对降低胶质瘤风险有保护作用。我们希望在基于人群的研究中调查他汀类药物使用对胶质瘤风险的影响。
我们在丹麦进行了一项基于人群的全国性病例对照研究，基于人群的医疗登记处。我们确定了所有在 2000 年至 2009 年期间首次诊断为组织学证实的胶质瘤的年龄在 20 至 85 岁之间的患者。这些病例按出生年份和性别与人群对照相匹配。自 1995 年以来，他汀类药物的使用情况分为短期使用（<5 年）和长期使用（5 年以上）。我们使用条件逻辑回归计算与他汀类药物使用相关的胶质瘤的比值比（OR），置信区间（CI）为 95%，并调整了潜在混杂因素。
共纳入 2656 例病例和 18480 例对照。与从未使用过他汀类药物的患者相比，长期使用他汀类药物的患者（OR=0.76；95%CI：0.59-0.98）的胶质瘤风险降低，并且与使用者的他汀类药物治疗强度呈负相关（OR=0.71；95%CI：最高强度为 0.44-1.15）。长期他汀类药物治疗与胶质瘤风险之间的负相关在≤60 岁的男性中更为明显（OR=0.40；95%CI：0.17-0.91），而在≥60 岁的男性中（OR=0.71；95%CI：0.49-1.03）则不明显。在≤60 岁的女性中也观察到了负相关（OR=0.28；95%CI：0.06-1.25），但在>60 岁的女性中则不明显（OR=1.23；95%CI：0.82-1.85）。
长期使用他汀类药物可能降低胶质瘤的风险。
